This study tested the hypothesis that simvastatin treatment can improve cardiovascular and autonomic functions and membrane lipoperoxidation, with an improved effect when applied to physically qualified ovariectomized rats. the other organizations. Tachycardic and bradycardic reactions were enhanced in both simvastatin-treated organizations. The vagal effect was improved in the qualified+simvastatin group and the sympathetic effect was decreased in the sedentary+simvastatin group. Hepatic lipoperoxidation was reduced in sedentary+simvastatin (21%) and qualified+simvastatin organizations (57%) compared to the sedentary group. Correlation analysis involving all animals shown that cardiac lipoperoxidation was negatively related to the vagal effect (r = -0.7) and positively correlated to the sympathetic effect (r = 0.7). In conclusion, improvement in cardiovascular and autonomic functions associated with a reduction of lipoperoxidation with simvastatin treatment was improved in qualified ...
Related Queries:. simvastatin alternative 40 mg simvastatin and side effects simvastatin best time to take rosuvastatin simvastatin guidelines simvastatin cyp3a4 zocor 40 mg high cholesterol simvastatin tabletti 40mg simvastatin can cause took too much simvastatin simvastatin tabs 20mg zocor side effect with alcohol zocor and anxiety simvastatin steroid cream new simvastatin guidelines ezetimibe simvastatina prezzo simvastatin safer alternatives zocor pins needles zocor my diet zocor loss appetite tac dung cua simvastatin simvastatin erythrocin bivirkninger ved bruk av simvastatin simvastatin together tricor lab work for simvastatin atenolol zocor tylenol zocor is simvastatin zestril interaction zocor atorvastatin against simvastatin equivalent dose simvastatin toxicity fda release simvastatin taking zocor drinking alcohol fda warning 80 mg simvastatin aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes accept d zocor male side effects hair loss with ...
Simvastatin (Zocor) is a cholesterol-lowering medication that blocks the production of cholesterol. Includes simvastatin side effects, interactions and indications. Also: Brand simvastatin quit, Cheapest simvastatin order online mastercard, Generic simvastatin order visa uk, Purchase simvastatin generico, Order now cheapest simvastatin otc, Low cost simvastatin pills, Simvastatin canada rezeptfrei, Simvastatin pills online mail order
Streptococcus pyogenes is a human pathogen that can manipulate host cell machinery in human umbilical vein endothelial cells (HUVEC), exploiting host cell endocytosis to become an intracellular pathogen. It is postulated that deep tissue infection is initiated by bacterial migration across the endothelial cell barrier. Deep tissue invasive S. pyogenes infection has been associated with persistent infections that potentially lead to sepsis and necrotizing fasciitis. Simvastatin, a common cholesterol-lowering drug, inhibits localization of Rho GTPase isoforms that regulate host cell endocytosis. We performed bioassays to examine how simvastatin may influence S. pyogenes invasion in HUVEC. Simvastatin treatment decreased S. pyogenes invasion 87±12%. Host cell actin stress fibers are typically disassembled in response to S. pyogenes infection; however, simvastatin treatment decreased actin stress fiber disassembly by 12% compared to control. Simvastatin decreased HUVEC binding to fibronectin by ...
Anti-atherosclerotic effects between a combined treatment with simvastatin plus hirudin and single simvastatin therapy in patients with early type 2 diabetes mellitus
BACKGROUND: Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations are associated with lower cardiovascular disease risk. In such populations, therefore, reducing LDL cholesterol may reduce the development of vascular disease, largely irrespective of initial cholesterol concentrations. METHODS: 20,536 UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive 40 mg simvastatin daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). Analyses are of the first occurrence of particular events, and compare all simvastatin-allocated versus all placebo-allocated participants. These intention-to-treat comparisons assess the effects of about two-thirds (85% minus 17%) taking a statin during the scheduled 5-year treatment period, which yielded an average difference in LDL cholesterol of 1.0 mmol/L (about two-thirds of the effect of actual use of 40 mg simvastatin
TY - JOUR. T1 - Effect of simvastatin on transforming growth factor beta-1-induced myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. AU - Park, Il Ho. AU - Park, Se Jin. AU - Cho, Jung Sun. AU - Moon, You Mi. AU - Moon, Jun Hyeok. AU - Kim, Tae Hoon. AU - Lee, Sang Hag. AU - Lee, Heung Man. PY - 2012/1/1. Y1 - 2012/1/1. N2 - Background: Statins are the most commonly prescribed drugs for the treatment of hypercholesterolemia. Statins exert not only lipid-lowering but also other cellular effects, including antifibrotic properties. The purpose of this study was to determine the effect of simvastatin on transforming growth factor (TGF)-beta-1-induced myofibroblast differentiation and collagen production in nasal polyp- derived fibroblasts (NPDFs) and to verify the mechanism of the effect of simvastatin in TGF-beta-1-induced myofibroblast differentiation in NPDFs. Methods: NPDFs were pretreated with simvastatin with or without mevalonate or Y-27643 for 2 hours ...
OBJECTIVES: To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages with differing risks of vascular disease. DESIGN: A model developed from a randomised trial was used to estimate lifetime risks of vascular events and costs of treatment and hospital admissions in the United Kingdom. SETTING: 69 hospitals in the UK. PARTICIPANTS: 20,536 men and women (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes. INTERVENTIONS: 40 mg simvastatin daily versus placebo for an average of 5 years. MAIN OUTCOME MEASURES: Cost effectiveness of 40 mg simvastatin daily expressed as additional cost per life year gained. Major vascular event defined as non-fatal myocardial infarction or death from coronary disease, any stroke, or revascularisation procedure. Results were extrapolated to younger and older age groups at lower risk of vascular disease than were studied directly, as well as to lifetime treatment. RESULTS: At the April 2005 UK
TY - JOUR. T1 - The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia. T2 - A SILHOUETTE Trial Sub-study. AU - Miller, Michael. AU - Dobs, Adrian S. AU - Yuan, Z.. AU - Battisti, W. P.. AU - Palmisano, J.. PY - 2006/2. Y1 - 2006/2. N2 - Objective: To determine if simvastatin effectively decreases the elevated levels of triglyceride (TG), TG-rich lipoproteins, and small, dense LDL particles, which are characteristic of diabetic dyslipidemia. Research design and methods: We conducted a prespecified analysis from a double-blind, placebo-controlled, randomized, 6-week crossover trial in patients with type 2 diabetes and low HDL-C (,40 mg/dL). Each patient was randomized to 1 of 6 possible treatment arms; each patient received simvastatin 80 mg, simvastatin 40 mg, and placebo over 3 periods. We used the validated vertical auto profile (VAP) method to directly assess TG-rich lipoproteins and LDL subclasses. We assessed the efficacy of simvastatin to ...
Simvastatin Simvastatin tablets What do simvastatin tablets do?SIMVASTATIN (Zocor(R)) blocks the bodys ability to make cholesterol. Simvastatin can help lower blood cholesterol for patients who are at risk of getting heart disease or a stroke. It is only for patients whose cholesterol level is not controlled by diet. Generic simvastatin tablets are available.
vytorin hexal billig kaufen. vytorin pflaster preis - vytorin online - pflaster vytorin preisvergleich: Apotheke Inc Medical Supplies in Sandusky, OH - Wellness.I get muscle cramps could this be a side effect of simvastatin 40 mg? Find answers now! No. 1 Questions & Answers Place. More questions about Health, Diet & Fitness.Erektion uveitis q10 vs lipitor can I switch from to simvastatin can you. And hiv meds medicamento para el colesterol kamagra jelly preisvergleich einnahme a de 40.Simvastatin Sandoz 40 mg filmomhulde tabletten is doeltreffend alleen of in combinatie met anionuitwisselaars zoals colestyramine en colestipol.Apotheke, Preisvergleich und Testberichte. Preisvergleich - Apotheke. Simvastatin Corax 40 mg - Filmtabletten - 100 ST Corax Darreichungsform: Filmtabletten.. 1 Package leaflet Simvastatin XXX 40 mg, film-coated tablets Simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains ...
Simvastatin Simvastatin Cost, Zocor Cheap Drugs, Buy Cheap Simvastatin Line, Where To Purchase Online Zocor Phoenix, Where To Purchase Cheap Zocor Houston, Average Cost Simvastatin Daily Use, Acheter Zocor En Ligne, Cheap Simvastatin Generic Buy, Zocor Buy Cheapest, Average Cost For Simvastatin, Zocor Generic Mail Order, Beställ Cheap Zocor Switzerland, Zocor Medication Cost, Cheapest Pharmacy Simvastatin, Order Simvastatin Generic Online Paypal, Cheapest Simvastatin, Where To Purchase Generic Zocor Atlanta, Combien Online Zocor San Diego, Acheter Zocor En Ligne Livraison Rapide, Achat Zocor Sans Ordonnance, Canadian Pharmacy Cheap Simvastatin, Zocor Cuanto Tiempo Antes, Zocor Cheap Overnight Delivery, Simvastatin Generic Cost, Simvastatin Kopen Online, Zocor How To Order, Zocor Generic Cheap No Prescription, Best Place To Buy Generic Simvastatin Online, Cheapest Branded Simvastatin, Can You Buy Zocor Online No Prescription, Acheter Du Zocor Sur Le Net, Genuine Zocor Buy, Where To Buy ...
The results of the multicenter, randomized ENHANCE trial seem to suggest that in patients with very high baseline LDL levels, such as those with HeFH, the combination of ezetimibe/simvastatin 10/80 mg does not result in significant changes in the mean carotid IMT at 2 years when compared with high-dose simvastatin 80 mg alone. There was also no difference in the incidence of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and need for revascularization, although this study was not powered to study clinical outcomes. The incidence of adverse events was similar. The LDL-lowering effect of ezetimibe/simvastatin was greater than that achieved with high-dose simvastatin alone ...
Access the full label. Generally a single dose at night. You should take simvastatin with water or other beverage. This medicine may be taken with or without food.. DOSE. The initial dose of simvastatin is usually 20 or 40 mg per day.. This medicine begins to work in about two weeks.. Your doctor may also prescribe lower doses, particularly if you are taking certain medications listed above or have certain types of kidney disease.. Continue taking simvastatin, unless your doctor tells you to stop. If you stop taking this medicine, your cholesterol levels may increase again.. Due to the increased risk of developing muscle injury, a dose of 80 mg should not be administered to patients who are beginning the treatment or to patients who already use of lower doses of simvastatin. The dose of 80 mg should only be used by people who: are taking simvastatin 80 mg chronically (for 12 months or more) without showing muscle injury or who need not take other drugs with simvastatin that would increase your ...
Easy simvastatin, Mail order simvastatin store canada, Simvastatin order shop otc, Order simvastatin buller, Cheap simvastatin mail order otc
MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of ...
JAMA 2000;283(19):2579-84. [42] Connolly VM, Kesson CM. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Diabetes Care 1996;19(5):419-22. [43] Robinson N, Lloyd CE, Stevens LK. Social deprivation and mortality in adults with diabetes mellitus. Diabet Med 1998;15(3):205-12. [44] Beckles G, Thompson-Reid P. Socioeconomic status of women with diabetes: United States, 2000. MMWR MOrb Mortal Wkly Rep 2002;51:147-8. [45] Wong MD, Shapiro MF, Boscardin WJ, et al. 130 mg/dL [122]. Several large, randomized clinical trials, including the Scandinavian Simvastatin Survival Study [146], the Antihypertensive and Lipid-Lowering Treatment to Prevent heart Attack Trial [147], the Heart Protection Study [148], and the Collaborative Atorvastatin Diabetes Study [149], have demonstrated that treatment with hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) results in significant primary and secondary prevention of CHD in individuals who have T2DM [150]. ...
Of the patients enrolled in this study, ≈70% (5356 patients) were women, more than any previous study of statins and prevention. The results of the present analysis are based on detailed analyses of the women in the MEGA study. In the women in the MEGA study, the incidence of events was lower for women than for men, and the risk for women tended to rise with age, similar to the findings in previous reports.1-3 The generally low incidence of events in women requires a large sample size to make a valid comparison, which may have contributed to the lack of studies of women to date. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS),11 Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial (ALLHAT-LLT),14 Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA),15 and Heart Protection Study (HPS)16 studied primary prevention, and Scandinavian Simvastatin Survival Study (4S),8 Long-Term Intervention With ...
The purpose of this study is to see if a drug called simvastatin (brand name Zocor) beneficially affects the level of certain molecules (such as proteins) in the spinal fluid of people. The molecules the investigators are measuring are thought to be important in the development of Alzheimers disease (AD), and the investigators are testing whether simvastatin can change proteins to a level that is associated with a reduced risk for AD.. Simvastatin has been approved by the United States Food and Drug Administration (FDA) for the treatment of high cholesterol and to reduce the risk of coronary artery disease. It is an investigational drug in this study.. Participants will be randomly assigned to Placebo or Simvastatin. The investigators and the participant will be blinded. Randomization will be stratified by age and gender.. This study is being funded by the National Institute on Aging. The investigators will take part in this study at the VA Puget Sound Health Care System.. This study will last ...
Statins are widely used and well tolerated cholesterol-lowering drugs, and when used for therapy purposes reduce morbidity and mortality from coronary heart disease. Simvastatin is one of nine known statins, specific inhibitors of hepatic enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting step of cholesterol biosynthesis, and is believed to reduce plasma cholesterol levels by decreasing the activity of this enzyme. Statin drugs represent the major improvement in the treatment of hypercholesterolemia that constitutes the main origin of atherosclerosis, leading to coronary heart disease. Although statins are generally safe, minor and severe adverse reactions are well known complications of statin use. Adverse events associated with simvastatin therapy are uncommon, but potentially serious. In this review some details about statins including their adverse effects in humans and animals, the effects of simvastatin on various intracellular and mitochondrial processes, and ...
Results 61 patients were recruited acute admissions unit at the Queen Elizabeth Hospital Birmingham between 2013 and 2015, with 31 patients randomised to simvastatin and 30 to placebo. Groups were well matched for baseline characteristics, pneumonia and sepsis severity, co-morbidities and biochemical and haematological parameters.. There was no significant difference in the primary end-point of change in NETS at day3/4. Directional neutrophil migration (chemotaxis) was significantly improved in patients who received simvastatin at day 3/4 (0.35 ± 0.16 μm/min vs. −0.15 ± 0.17 μm/min; p = 0.033). Simvastatin was well tolerated with no SUSARS, even with the co-prescription of macrolides. At 6-months, patients in the simvastatin group were less likely to have been admitted to hospital or died compared to those in the placebo group (OR: 0.44; 95% CI: 0.21-0.91; p = 0.02) (Figure 1). ...
We evaluated the relationship between statin use and risk of new onset AP in a large integrated healthcare setting. Our primary analysis focused on simvastatin as previous literature had suggested a potential increased risk of pancreatitis with this agent. Simvastatin was also the most commonly prescribed statin agent within the KPSC health system during the study period. Although there was an increased prevalence of established risk factors for pancreatitis among simvastatin users, we found an overall 38% reduction in the crude incidence of AP among patients taking simvastatin compared with the reference population. In multivariable analysis, after adjusting for the effect of gallstone disorders, chronic alcohol dependence and hypertriglyceridaemia, simvastatin use was associated with marked reduction in risk of developing AP with adjusted RR of 0.29 (70% risk reduction). A similar effect was observed with atorvastatin, adjusted RR 0.33, suggesting a potential class-effect. There was evidence ...
Consumer Medicine Information (CMI) about APO-Ezetimibe/Simvastatin (Ezetimibe/Simvastatin) intended for persons living in Australia.
The 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339:1349-57. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993;64:354-8. 26. Mensink RP, Lebbink WJ, Lobbezoo IE et al. Diterpene composition of oils from Arabica and Robusta coffee beans and their effects on serum lipids in man. J Intern Med 1995;237:543-50. 27. Sharp D, Blinderman L, Combs KA et al. Cloning and gene defects in microsomal triglyceride transfer protein associated ...
Question - Metabolic panel, creatinine, ketones, proteinuria, cholesterol, on simvastatin, enalapril, diovan, diltiazem cd. Ask a Doctor about uses, dosages and side-effects of Diovan, Ask a Nephrologist
We show that, consistent with studies of ezetimibe coadministration with simvastatin in adults, significant incremental decreases of approximately 15% in LDL-C levels compared with administration of simvastatin alone were achieved within 6 weeks of treatment. These decreases were sustained throughout the subsequent 26-week, double-blind phase of the study in adolescent subjects with HeFH. Prolonged reductions were maintained through 53 weeks in the overall study population. Significantly greater reductions from baseline in total cholesterol, non-HDL-C, and apo B levels were also documented after 6 weeks and again at 33 weeks in subjects who received coadministration of ezetimibe with simvastatin compared with simvastatin monotherapy. These parameters also remained at reduced levels throughout the final 20-week phase of the study.. Mean incremental LDL-C reductions associated with coadministration of ezetimibe were consistent across the 10-, 20-, and 40-mg simvastatin dosing groups after 6 weeks ...
Cholesterol-lowering drug. 20mg Pills of the cholesterol-lowering drug Simvastatin on a heart shaped background. This drug reduces the levels of low-density lipoprotein (LDL) cholesterol (bad cholesterol) in the bloodstream. High levels of LDL cholesterol (hypercholesterolaemia) are a major cause of heart disease and strokes. Simvastatin works by blocking the effects of the enzyme HMG-CoA reductase, which normally causes the body to produce LDL cholesterol from foods. - Stock Image C004/4198
To correlate peripheral blood mononuclear cell gene expression changes with tumor gene expression changes, and to identify blood gene markers that may predict Simvastatin biological effects. VI. Abstract of Research Proposal In no more than 300 words, describe concisely the specific aims, hypotheses, methodology and approach of the application, indicating where appropriate the applications importance to science or medicine. The abstract must be self-contained so that it can serve as a succinct and accurate description of the application when separated from it. Please use lay terms. If this not possible, the technical and medical terms should be explained in simple language. We hypothesize that Simvastatin administration would result in selective killing of the basal subtype of breast cancer, in particular, CD44+/CD24- breast cancer cells in primary tumor. We further hypothesize that tumor genomic changes would correlate with tumor response to Simvastatin. We are also looking to correlate ...
PURPOSE:To evaluate the effect of a local application of simvastatin gel in repairing bone defects in the femurs of rabbits.METHODS:Two standard surgical cavities were created in the femoral epiphysis of 18 rabbits. In the simvastatin group (SG), the cavities were filled with a collagen sponge soaked in 0.5 ml of a simvastatin (1 mg) gel, and the cavities were covered with a biological membrane. The bone cavities in the second group (control group) were filled with a blood clot and covered with a biological membrane. On the 7th, 21st and 42nd days, six animals in each group were euthanized, and the femurs were subject to histological evaluation (vascularity, fibrosis, reactive bone formation, osteoblasts, and osteoclasts) and immunohistochemical (anti-VEGF and anti-osteocalcin) analysis. The results were analyzed using a Wilcoxon test (p,0.05).RESULTS:There were significant differences between the two groups: the SG had greater scores in comparison with the CG in terms of the degree of ...
The aim of the present work was to shed light on the role played by the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and memory consolidation in rodents through the inhibition of the key and rate-limiting enzyme 3-hydroxy 3-methylglutaryl Coenzyme A reductase (HMGR) both in vivo and in vitro with simvastatin. Three-month-old male Wistar rats treated for 21 days with simvastatin or vehicle were tested in the social interaction, elevated plus-maze, and inhibitory avoidance tasks; after behavioral testing, the amygdala, hippocampus, prefrontal cortex, dorsal, and ventral striatum were dissected out for biochemical assays. In order to delve deeper into the molecular mechanisms underlying the observed effects, primary rat hippocampal neurons were used. Our results show that HMGR inhibition by simvastatin induces anxiogenic-like effects in the social interaction but not in the elevated plus-maze test, and improves memory consolidation in the inhibitory ...
Merck announced that Juvisync, a fixed-dose combination product containing the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin is now available.
Multiple studies have demonstrated the value of lipid-lowering therapy for both the primary and secondary prevention of CHD. Because these studies have not been specifically oriented toward the elderly, the value of such therapy in older individuals has been questioned. However, substantial data from subanalyses of older subjects within existing studies are available, and in addition, there are now several studies in progress that are specifically oriented toward this patient group.. The Scandinavian Simvastatin Survival Study (4S) demonstrated important reductions in coronary event-related morbidity and mortality in patients with known CHD.48 In a post hoc analysis from this study, it was demonstrated that cholesterol lowering with simvastatin produced similar reductions in relative risk for major coronary events in patients ≥65 years of age compared with younger patients. Thus, CHD mortality was reduced 42% in subjects ,65 years of age and 43% in those ≥65 years of age. Likewise, ...
This long-term in-vivo human study shows that effective and protracted lipid-lowering therapy by simvastatin is associated with a significant regression of atherosclerotic lesions (10,13). Interestingly, in this cohort of asymptomatic patients presenting with untreated hypercholesterolemia and atherosclerotic lesions of the aorta or carotid artery, similar regression was noticed in both vascular territories. In addition, the group of patients with a more aggressive hypolipidemic effect achieved an earlier and more marked reduction of the asymptomatic atherosclerotic lesions. Other investigators using combined surface and transesophageal MRI in the thoracic aorta have confirmed this observation (15).. Recently, Jensen et al. (16) reported similar results in the coronary circulation in patients with hemodynamically non-significant coronary stenoses (,50% stenoses) after 15 months of simvastatin treatment. This intravascular ultrasound (IVUS) study showed that statin treatment induces coronary ...
Purchase Cheap Zocor without prescription. Zocor (Simvastatin) is an hmg-coa reductase inhibitor or «statin» used to lower bad cholesterol (LDL) and triglyceride levels in your blood or to raise good cholesterol (HDL) levels in adults. Generic Zocor is one the best medications proven to lower bad cholesterol! Generic Zocor may also be marketed as:Lipex, Simovil, Simvastatin, Simvotin, Zocord ...
Statins affect the production of long chain polyunsaturated fatty acids (PUFA), both in vitro and in vivo. Various studies have shown the effects of statins on the pattern of n-6 fatty acids (FA), but limited attention has been paid to the n-3 FA. We investigated, in THP-1 and in HepG2 cells, the effects of simvastatin on the conversion of the 18C FA precursors in the n-3 and n-6 series, [1-14C] (alpha)-linolenic acid ((alpha)-LNA) and [1- 14C] linoleic acid (LA) respectively, and on the metabolism of [1-14C] stearic acid (SA). THP-1 cells, as in the case of LA, actively converted (alpha)-LNA to its products, and after simvastatin treatment, the total conversion was significantly increased (from 57.2 (plus or minus) 7.2 to 74.3 (plus or minus) 8.5%, p , 0.05). HepG2 cells also converted LA and (alpha)-LNA, but simvastatin increased significantly only the conversion of LA (9.5 (plus or minus) 1.9% versus 23.8 (plus or minus) 5.1%, p , 0.02). SA conversion was similar in untreated cells (about ...
Our results support the hypothesis that cholesterol status of neurons is crucial for excitotoxicity since we found that inhibition of cholesterol synthesis prevents NMDA-induced neuronal death. Two different inhibitors of cholesterol synthesis, the inhibitor of Δ14-Δ7 reductase AY9944 and the inhibitor of HMGCoA reductase simvastatin, protect from excitotoxic cell death in pure neuronal cultures (Figures 2 and 3⇑). Both compounds inhibited cholesterol synthesis, but contrary to simvastatin, AY4499 does not inhibit isoprenylation or farnesylation.22 In agreement with results previously reported,10 we found that simvastatin protected against excitotoxicity at nanomolar concentrations and required pretreatments ,2 days to provide neuroprotection.10,11 These 2 observations suggest that the effect of simvastatin on neuroprotection relays on its effect on cholesterol synthesis, because the inhibition of prenylation by statins occurs at higher concentrations and with shorter exposure times than ...
The landmark Scandinavian Simvastatin Survival Study (4S) published in 1994, may well be remembered as the study that finally put to rest many of the apprehensions and misconceptions regarding lipid-lowering therapy.. Duffy and Meredith 19961 ...
Lowering of low-density lipoprotein cholesterol is well achieved by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). Statins inhibit the conversion of HMG-CoA to mevalonate, a precursor for cholesterol and coenzyme Q10 (CoQ10). In HepG2 cells, simvastatin decreased mitochondrial CoQ10 levels, and at higher concentrations was associated with a moderately higher degree of cell death, increased DNA oxidative damage and a reduction in ATP synthesis. Supplementation of CoQ10, reduced cell death and DNA oxidative stress, and increased ATP synthesis. It is suggested that CoQ10 deficiency plays an important role in statin-induced hepatopathy, and that CoQ10 supplementation protects HepG2 cells from this complication. © 2007 Elsevier Inc. All rights reserved ...
Cholesterol-lowering drug. Hands holding a blister pack and pills of the drug Simvastatin. This drug reduces the levels of low-density lipoprotein (LDL) cholesterol in the body. High levels of LDL cholesterol (hypercholesterolaemia) are a major cause of heart disease and strokes. It works by blocking the effects of the body enzyme HMG-CoA reductase, which normally causes the body to produce LDL cholesterol from foods. Simvastatin & other similar drugs (known as statins) have also been reported to increase bone density. This means that they could potentially be used as a treatment for osteoporosis (brittle bones), which affects many women after the menopause. - Stock Image M625/1132
Although more potent cholesterol reduction has previously been linked with a reduction in cardiovascular events (the lower is better paradigm), concerns have remained about the safety of using high doses of cholesterol-lowering medications to this end. The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) aimed to establish more reliably the balance between efficacy and safety of intensive low-density lipoprotein (LDL) lowering.. Six thousand and thirty-one participants were randomly assigned to 80 mg simvastatin daily and 6033 to 20 mg simvastatin daily. Over an average of 6.7 years of follow-up, simvastatin 80 mg was noted to give an average of 0.35 mmol/l greater reduction in LDL-cholesterol compared with allocation to 20 mg. A 6% further reduction in vascular events was seen due to this reduction in LDL-cholesterol, consistent with what has been noted in other statin trials. Although there were no significant differences in the number of ...
Very few vytorin is indicated to reduce the risk of major. ;Annual spending on statins exceeded $19 million in 2005, ezetimibe (in the form of vytorin and; vytorin 10mg/20mg tablets manufactured by merck sharp ; dohme product of new zealand. ;S ($mrk) cholesterol franchise, an fda advisory panel shot down its bid to tout vytorin and zetia as preventives; 17 nov 2014 the long-awaited results of a trial of the cholesterol-lowering drug vytorin showed modest benefit and indicated that adding a non-statin drug to; vytorin is available for oral use as tablets containing 10 mg of ezetimibe, and 10 mg of (vytorin 10/10), 20 mg of simvastatin (vytorin 10/20), 40 mg of; compare prices and print coupons for vytorin and other high cholesterol drugs at cvs, walgreens, and other pharmacies ...
Statins are widely being used for the treatment of a variety of conditions beyond their original indication for lowering cholesterol. We have previously reported that simvastatin affected the dopaminergic system in the rat brain. This study aims to investigate locomotor and anxiety effects along with the regional changes of N-methyl-d-aspartate (NMDA) receptors in the rat brain after 4-week administration of simvastatin. Hyperlocomotive and anxiolytic-like activities in the rat were observed after chronic administration of high dose simvastatin (10 mg/kg/day). Distributions and alterations of NMDA receptors in the post-mortem rat brain were detected by [3H] MK-801 binding autoradiography. Simvastatin increased [3H] MK-801 binding, predominantly in the prefrontal cortex (20%, p = 0.003), primary motor cortex (20%, p | 0.001), cingulate cortex (28%, p | 0.001), hippocampus (41%, p | 0.001), caudate putamen (30%, p = 0.029), nucleus accumbens (27%, p = 0.035) and amygdala (45%, p | 0.001) compared to
TY - JOUR. T1 - Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. AU - Jacobson, Jeffrey R.. AU - Barnard, Joseph W.. AU - Grigoryev, Dmitry N.. AU - Ma, Shwu Fan. AU - Tuder, Rubin M.. AU - Garcia, Joe G N. PY - 2005/6. Y1 - 2005/6. N2 - Therapies to limit the life-threatening vascular leak observed in patients with acute lung injury (ALI) are currently lacking. We explored the effect of simvastatin, a 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor that mediates endothelial cell barrier protection in vitro, in a murine inflammatory model of ALL C57BL/6J mice were treated with simvastatin (5 or 20 mg/kg body wt via intraperitoneal injection) 24 h before and again concomitantly with intratracheally administered LPS (2 μg/g body wt). Inflammatory indexes [bronchoalveolar lavage (BAL) myeloperoxidase activity and total neutrophil counts assessed at 24 h with histological confirmation] were markedly increased after LPS alone but significantly ...
UPDATED 12/15/2011] FDA notified the public that it has revised the dose limitation for simvastatin from 10 mg to 20 mg when it is co-administered with the cardiac drug amiodarone. The simvastatin drug labels (Zocor and generics, Vytorin) have been updated to reflect this correction.. [Posted 06/08/2011]. ISSUE: FDA notified healthcare professionals that it is recommending limiting the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage. Patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the same class. This risk appears to be higher during the first year of treatment, is often the result of interactions with certain medicines, and is frequently associated with a genetic predisposition toward simvastatin-related myopathy. The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney ...
Background-Pulmonary arterial hypertension (PAH) is a progressive disease that causes exercise limitation, heart failure, and death. We aimed to determine the safety and efficacy of aspirin and simvastatin in PAH. Methods and Results-We performed a randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH receiving background therapy at 4 centers. A total of 92 patients with PAH were to be randomized to aspirin 81 mg or matching placebo and simvastatin 40 mg or matching placebo. The primary outcome was 6-minute walk distance at 6 months. Sixty-five subjects had been randomized when the trial was terminated by the Data Safety and Monitoring Board after an interim analysis showed futility in reaching the primary end point for simvastatin. After adjustment for baseline 6-minute walk distance, there was no significant difference in the 6-minute walk distance at 6 months between aspirin (n=32) and placebo (n=33; placebo-corrected difference
Background Recent trials in acute myocardial infarction indicate that intensive and early statin therapy that lowers low-density lipoprotein cholesterol (LDL-C) to ≤ 70 mg dL−1 is beneficial. The combination of statins with ezetimibe, a newly developed cholesterol-absorption inhibitor, can lead to a further reduction in LDL-C of up to 26%. In this study, we examined the rapidity and intensity of the lipid-lowering effect of ezetimibe co-administered with simvastatin immediately after myocardial infarction.. Materials and methods Sixty patients admitted for acute myocardial infarction were randomized to receive either simvastatin 40 mg (SIMVA), a combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA), or no lipid-lowering drugs (NLLD) and had their lipid levels assessed 2, 4 and 7 days later.. Results At baseline, cardiovascular risk factors were similar in all three groups [mean (SD) LDL-C of 141 (36) mg dL−1]. At days 2 , 4 and 7 there was no significant change in mean LDL-C ...
The results of the Heart Protection Study (HPS), which compared simvastatin 40 mg daily to placebo, provide considerable insight into the importance of LDL-C lowering in the general population and, in particular, patients with diabetes (27). In the overall study involving ,20 000 subjects, similar risk-ratio reductions were observed in subjects with baseline LDL-C ,3.5 mmol/L, 3.0 to 3.5 mmol/L and ,3.0 mmol/L. In the subgroup with diabetes (n=5963, including 615 people with type 1 diabetes), treatment with 40 mg simvastatin daily resulted in a 27% reduction in cardiovascular (CV) events and a 25% reduction in stroke relative to treatment with placebo. The risk reduction was similar in the cohorts with and without diabetes, and the treatment benefit was independent of baseline HDL-C and LDL-C levels (LDL-C ,3.0 mmol/L or ≥3.0 mmol/L), sex, vascular disease, type of diabetes (type 1 vs. type 2) and glycated hemoglobin (A1C) (26). These results emphasized the benefits of statin treatment ...
Methods: We did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National Adult Reading Test, Wechsler Abbreviated Scale of Intelligence, Graded Naming Test, Birt Memory and Information Processing Battery (BMIPB), Visual Object and Space Perception battery (cube analysis), Frontal Assessment Battery (FAB), and Paced Auditory Serial Addition Test. Neuropsychiatric status was assessed using the Hamilton Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire. HRQoL was assessed using the self-reported 36-Item Short Form Survey (SF-36) version 2. Assessments were done at study entry, 12 months, and 24 months. Patients, treating physicians, and outcome assessors were masked to treatment allocation. Analyses were by ...
Background:Recent studies suggest that the reported protective effects of statins (HMG-CoA reductase inhibitors) against community-acquired pneumonia (CAP) and sepsis in humans may be due to...
study: a patient treated with atorvastatin, 20 mg/d, died of Ezetimibe/simvastatin reduced LDL-C levels by more than chronic obstructive pulmonary disease (not considered 50% from baseline at these doses, fulfilling the ADA rec- ommendation of a 30% to 40% reduction from baseline.2 Laboratory adverse events occurred in 8 patients (1.6%) This study also confirmed the superior attainment of LDL- in the ezetimibe/simvastatin group and 10 patients (1.4%) C levels of less than 70 mg/dL in high-risk patients with in the atorvastatin group. Drug-related LAEs occurred in 3 ezetimibe/simvastatin vs atorvastatin and did so across a patients in both treatment assignments. No serious LAEs wider range of dosages than previously reported.20 Thus, occurred, and no patients discontinued study participation these results add to the clinical experience with ezetimibe/ simvastatin, affirming its effectiveness in the management No patient had a creatine kinase elevation 10 or more of high LDL-C levels11-13,20,21 ...